MGO One Seven LLC Acquires 43 Shares of Vertex Pharmaceuticals Incorporated $VRTX

MGO One Seven LLC grew its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 2.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,822 shares of the pharmaceutical company’s stock after purchasing an additional 43 shares during the period. MGO One Seven LLC’s holdings in Vertex Pharmaceuticals were worth $811,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. United Services Automobile Association bought a new stake in Vertex Pharmaceuticals during the first quarter worth about $2,933,000. Lee Johnson Capital Management LLC bought a new stake in Vertex Pharmaceuticals during the second quarter worth about $721,000. SteelPeak Wealth LLC bought a new stake in Vertex Pharmaceuticals during the second quarter worth about $10,059,000. Moody Lynn & Lieberson LLC lifted its stake in Vertex Pharmaceuticals by 1.4% during the second quarter. Moody Lynn & Lieberson LLC now owns 58,077 shares of the pharmaceutical company’s stock worth $25,856,000 after purchasing an additional 822 shares during the last quarter. Finally, New England Research & Management Inc. bought a new stake in Vertex Pharmaceuticals during the second quarter worth about $472,000. Institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Price Performance

Shares of NASDAQ:VRTX opened at $408.61 on Friday. Vertex Pharmaceuticals Incorporated has a 1 year low of $362.50 and a 1 year high of $519.88. The company has a market cap of $104.76 billion, a PE ratio of 29.21 and a beta of 0.43. The stock’s 50-day moving average is $394.46 and its 200 day moving average is $437.23.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.24 by $0.28. The company had revenue of $2.94 billion for the quarter, compared to the consensus estimate of $2.90 billion. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.Vertex Pharmaceuticals’s revenue was up 11.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($12.83) EPS. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. Analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on VRTX shares. Wells Fargo & Company upgraded Vertex Pharmaceuticals from an “equal weight” rating to an “overweight” rating and set a $460.00 price objective on the stock in a report on Wednesday, August 6th. Evercore ISI decreased their price objective on Vertex Pharmaceuticals from $510.00 to $475.00 and set an “outperform” rating on the stock in a report on Thursday, September 11th. Stifel Nicolaus decreased their price objective on Vertex Pharmaceuticals from $494.00 to $455.00 and set a “hold” rating on the stock in a report on Tuesday, August 5th. Guggenheim decreased their price objective on Vertex Pharmaceuticals from $558.00 to $546.00 and set a “buy” rating on the stock in a report on Wednesday, August 6th. Finally, Morgan Stanley decreased their price objective on Vertex Pharmaceuticals from $439.00 to $438.00 and set an “equal weight” rating on the stock in a report on Friday, October 10th. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and twelve have assigned a Hold rating to the company. According to data from MarketBeat, Vertex Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $494.38.

Insiders Place Their Bets

In other news, Director Bruce I. Sachs acquired 5,000 shares of the business’s stock in a transaction on Wednesday, August 6th. The shares were acquired at an average cost of $389.68 per share, with a total value of $1,948,400.00. Following the transaction, the director owned 45,000 shares in the company, valued at $17,535,600. The trade was a 12.50% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.